

RNS Reach Story

[Go to market news section](#)



Company Fulcrum Pharma PLC
TIDM FUL
Headline Contract Win
Released 07:01 11-Oct-07
Number 5084F

.fulcrum>

RNS Number:5084F
 Fulcrum Pharma PLC
 11 October 2007

FULCRUM PHARMA PLC
 ("the Group" or "the Company")

Fulcrum wins contract to execute a phase III clinical oncology project in Japan

Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services company is pleased to announce that its Japanese subsidiary has won a contract to execute a phase III clinical oncology development study in Japan on behalf of a major Pharma company. The project runs from September 2007 for four years and is worth over 600 million JPY (over £2.5 million) in fees. In conjunction with other contracts already secured, this contract will mean that at current capacity, Fulcrum's Japanese subsidiary has a virtually full order book for the next two years.

Fulcrum has established itself in Japan as a specialist oncology clinical research organization where it now conducts studies for a range of Japanese companies, global pharma and Japanese government funded academic groups.

Alastair Devlin, Director of Japanese Strategy of Fulcrum Pharma, said: "We are delighted to win this contract with a major Pharma company which has recognised our strength in oncology. Cancer is the leading cause of death in Japan which is the world's largest oncology market."

For further information, please contact:

Fulcrum Pharma PLC
 Jon Court, Chief Executive

Tel: 0870 710 7152

Seymour Pierce
 Jonathan Wright

Tel: 0207 107 8000

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that provides global expertise to achieve drug development and regulatory approval milestones.

Fulcrum Pharma offers immediate access to a highly credible, integrated development team that provides strategic and operational leadership required to ensure that new drugs move smoothly from discovery research to product approval

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange

This information is provided by RNS
The company news service from the London Stock Exchange

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

©2007 London Stock Exchange plc. All rights reserved